InNeuroCo has been acquired by Integer
The owners of InNeuroCo has sold the company to Integer (NYSE:ITGR).
Founded in 2014 and headquartered in Pembroke Pines, Florida, InNeuroCo is a leading founder-owned designer and contract manufacturer of ultra-precise, highly engineered neurovascular catheters. InNeuroCo’s primary products are single-use catheters principally used in interventional neurovascular procedures for the treatment of ischemic strokes and aneurysms. Offering turnkey product design and development, supported by comprehensive domestic manufacturing capabilities, InNeuroCo serves as a mission-critical supply partner to the world’s preeminent medical device OEMs.
With approximately US$1.4 billion in annual revenue, Integer is one of the largest medical devices outsource manufacturers in the world, serving the cardiac, vascular, rhythm management and neuromodulation markets.
Oaklins TM Capital in the US served as the exclusive financial advisor to InNeuroCo in its sale to Integer (NYSE:ITGR).
Marc Litzenberg
President and CEO, InNeuroCo
Sprechen Sie mit dem Deal-Team
James McLaren
Oaklins TM Capital
John Dean
Oaklins TM Capital
Michael S. Goldman
Oaklins TM Capital
Bradley S. Goldstein
Oaklins TM Capital
Matthew Halbig
Oaklins TM Capital
Relevante Transaktionen
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Weitere InformationenbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Weitere InformationenBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Weitere Informationen